Ventripoint Announces Adoption of Semi-Annual Reporting (SAR)

About this update from Ventripoint Diagnostics Ltd.

Ventripoint Announces Adoption of Semi-Annual Reporting (SAR) (TheNewswire)     Toronto, Ontario – TheNewswire - May 29, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”)(TSXV:VPT) announces adoption of semi-annual financial reporting ("SAR"). This news release is being issued and filed pursuant to Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").   The CBO 51-933 pilot program permits eligible venture issuers to voluntarily move from quarterly to a semi-annual financial reporting framework. The Company has determined that it meets the eligibility criteria. By adopting SAR, Ventripoint aims to reduce the administrative and financial burden associated with quarterly reporting that will allow management to focus additional time and resources on advancing commercialization initiatives, business development activities and other business objectives.   As a result of adopting SAR, the Company will not file interim financial statements and related Management's Discussion and Analysis ("MD&A") for the three-month period ending March 31 and the nine-month period ending September 30 of each applicable fiscal year. Ventripoint will continue to file audited annual financial statements (due within 120 days of December 31) and six-month interim financial reports and related MD&A (due within 60 days of June 30). Should the Company cease to continue participating in the SAR pilot program, it will announce it in a future news release.   The Company remains committed to timely and transparent disclosure and will continue to provide timely disclosure regarding exploration progress, corporate developments, and other material information in accordance with Canadian securities regulations.   About Ventripoint Diagnostics Ltd.   Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patien...

View stock analysis, news, and events for Ventripoint Diagnostics Ltd.